<DOC>
	<DOC>NCT01378962</DOC>
	<brief_summary>This single-arm, open-label study will evaluate the efficacy and safety of Tarceva (erlotinib) in patients with locally advanced or metastatic non-small cell lung cancer. Patients will receive daily oral doses of 150 mg Tarceva. The anticipated time on study treatment is 12 months.</brief_summary>
	<brief_title>A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Adult patients, &gt;/=18 years of age Locally advanced or metastatic nonsmall cell lung cancer Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) Eastern Cooperative Oncology Group (ECOG) performance status 02 Life expectancy over &gt;/=12 weeks Adequate hematological, liver, or kidney function Previous therapy against epidermal growth factor receptor for metastatic disease Treatment with investigational drug during the 3 weeks before enrollment History of neoplasm Patients with symptomatic cerebral metastases Unstable systemic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>